Galiximab
Monoclonal antibody
N
Y (what is this?) (verify) Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma.[1] As of September 2009[update], it is undergoing Phase III clinical trials.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[3]
References
- ^ Ebadi M, Sadeghi MA, Reddy NM, Rezaei N (2020). "Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma". In Rezaei M (ed.). Cancer immunology: cancer immunotherapy for organ-specific tumors (Second ed.). Cham: Springer Nature. p. 178. ISBN 978-3-03-057949-4.
- ^ "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
- ^ WHO Drug Information
External links
- Official website
- v
- t
- e
Immunosuppressive drugs / Immunosuppressants (L04)
(initiation)
| Antimetabolites |
|
|---|---|
| Macrolides/ other IL-2 inhibitors | |
| IMiDs |
(reception)
| IL-1 receptor antagonists | |
|---|---|
| mTOR |
| Antibodies |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -cept (Fusion) |
- Avacopan
- Baricitinib
- Bimekizumab
- Blisibimod
- Briakinumab
- Brodalumab
- Canakinumab
- Crovalimab
- Danicopan]
- Deucravacitinib
- Efgartigimod alfa (+hyaluronidase)
- Etrasimod
- Filgotinib
- Fingolimod
- Guselkumab
- Iptacopan
- Itacitinib
- Ixekizumab
- Netakimab
- Olokizumab
- Ozanimod
- Peficitinib
- Pegcetacoplan
- Ponesimod
- Ravulizumab
- Risankizumab
- Ritlecitinib
- Rozanolixizumab
- Sarilumab
- Satralizumab
- Siltuximab
- Siponimod
- Sirukumab
- Spesolimab
- Sutimlimab
- Tildrakizumab
- Tofacitinib
- Upadacitinib
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
